Jan 30, 2025, 17:27
Thor Halfdanarson: Radiosensitivity of NET in Locally Advanced G2 Pancreatic Tumor Treated with CAPTEM and CRT
Thor Halfdanarson, Vice President of the North American Neuroendocrine Tumor Society, shared on X:
“A reminder that NETs are radiosensitive tumors. Locally advanced, nonmetastatic, unresectable (extensive vascular involvement, cavernous portal vein transformation) G2 panc NET (Ki67 9%). CAPTEM x12 with good partial response, followed by CRT with capecitabine. 23 months post CRT.”
More posts featuring Thor Halfdanarson.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 30, 2025, 17:14
Jan 30, 2025, 17:01
Jan 30, 2025, 15:37
Jan 30, 2025, 15:24
Jan 30, 2025, 15:16